Emerging Role of Novel Therapeutics

The recent United States Food and Drug Administration (FDA) approval of omalizumab for the treatment of food allergy has highlighted the potential of targeting the allergic pathways driving food allergy. Many promising therapeutic strategies are emerging that target different aspects of these pathways including immunoglobulin E, interleukin-4 receptor α, alarmins, and Bruton's tyrosine kinase. Several of these novel therapeutics have already been FDA approved for the treatment of other atopic diseases, greatly facilitating their potential translation to food allergy. Further research on these therapeutics can expand the tools available to allergists allowing them to better tailor therapeutics to the specific circumstances and needs of their patients.